The Global Burden of Peripheral Arterial Disease (PAD): Epidemiology and Statistics
I. Introduction to Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease (PAD) is a prevalent and progressive circulatory condition characterized by the narrowing of arteries outside of the heart and brain, most commonly affecting the arteries supplying blood to the limbs. This reduction in blood flow, primarily to the legs, can lead to a range of symptoms from claudication (pain during exercise) to critical limb ischemia, which can result in amputation and significantly impair quality of life. Beyond its localized effects, PAD is a strong indicator of systemic atherosclerosis and is associated with an increased risk of cardiovascular morbidity and mortality, including heart attack and stroke. Understanding the global burden of PAD, its epidemiological trends, and associated risk factors is crucial for developing effective public health strategies and clinical interventions.
II. Global Epidemiology of PAD
A. Prevalence and Incidence
The global prevalence and incidence of PAD have shown a significant increase over the past few decades, posing a substantial challenge to global health systems. According to the Global Burden of Disease (GBD) 2019 database, the number of individuals aged 40 years and older living with PAD reached an estimated 113 million in 2019 (95% uncertainty interval [UI] 99.2–128.4), with a global prevalence of 1.52% (95% UI 1.33–1.72) [1]. This represents a considerable rise from 1990, indicating a growing public health concern [1].
Projections for the future burden of PAD are even more striking. A population-based study forecasting the global burden of PAD from 2021 to 2050 estimates a dramatic increase in cases. The number of PAD cases worldwide is projected to increase by 220% by 2050, reaching an estimated 360 million people globally (95% uncertainty interval, 270 to 450) [2]. This anticipated surge underscores the urgent need for enhanced preventive measures and management strategies.
B. Mortality Rates and Disability-Adjusted Life Years (DALYs)
The impact of PAD extends beyond prevalence to significant mortality and disability. While some studies suggest a downward trend in the incidence, mortality, and DALYs of PAD in recent decades, particularly in certain regions [3], the overall burden remains substantial. In 2019, PAD contributed to approximately 74.1 thousand deaths globally [4].
Disability-Adjusted Life Years (DALYs), a measure that combines years of life lost due to premature mortality and years lived with disability, highlight the profound impact of PAD on global health. The total DALYs attributable to modifiable risk factors in 2019 accounted for 69.4% (64.2–74.3) of total peripheral artery disease DALYs [1]. The age-standardized mortality is expected to double by 2050, while DALYs are forecasted to rise from 19.7 to 33.1 per 100,000 [2]. These figures emphasize the chronic and debilitating nature of PAD and its significant contribution to the global burden of disease.
III. Key Risk Factors for PAD
Peripheral Arterial Disease is a multifactorial condition, with its development and progression strongly linked to a combination of modifiable and non-modifiable risk factors. Understanding these factors is paramount for effective prevention and management strategies.
A. Modifiable Risk Factors
Modifiable risk factors are those that can be altered through lifestyle changes or medical interventions, offering significant opportunities for reducing the burden of PAD.
1. Smoking
Smoking is unequivocally the most potent and prevalent modifiable risk factor for PAD. Tobacco use, including both active smoking and exposure to secondhand smoke, significantly accelerates the atherosclerotic process, leading to arterial damage and narrowing. Smokers have a two to four times higher risk of developing PAD compared to non-smokers, and continued smoking after a PAD diagnosis is associated with worse outcomes, including increased rates of amputation and mortality [5].
2. Diabetes Mellitus
Diabetes Mellitus is another major risk factor, contributing to both the development and severity of PAD. High blood glucose levels can damage blood vessels, leading to microvascular and macrovascular complications. Diabetic patients often develop PAD at a younger age, experience more rapid progression, and have a higher incidence of critical limb ischemia [6]. The presence of diabetes also complicates PAD management and increases the risk of adverse cardiovascular events.
3. Hypertension
Hypertension, or high blood pressure, exerts chronic stress on arterial walls, promoting endothelial dysfunction and the formation of atherosclerotic plaques. It is a well-established independent risk factor for PAD, and effective blood pressure control is crucial in mitigating its impact on arterial health [7].
4. Dyslipidemia
Dyslipidemia, characterized by abnormal levels of lipids in the blood (e.g., high LDL cholesterol, low HDL cholesterol, high triglycerides), plays a central role in the pathogenesis of atherosclerosis. Elevated cholesterol levels contribute to plaque formation and arterial narrowing, increasing the risk of PAD [8]. Lipid-lowering therapies are a cornerstone of PAD prevention and management.
5. Obesity and Sedentary Lifestyle
Obesity and a sedentary lifestyle are closely linked to several other cardiovascular risk factors, including diabetes, hypertension, and dyslipidemia. These factors collectively contribute to systemic inflammation and endothelial dysfunction, thereby increasing the risk of PAD. Promoting physical activity and healthy weight management are vital for reducing PAD incidence and improving patient outcomes [9].
B. Non-Modifiable Risk Factors
Non-modifiable risk factors are inherent and cannot be changed, but they help identify individuals at higher risk for PAD.
1. Age
Age is the strongest non-modifiable risk factor for PAD. The prevalence of PAD significantly increases with advancing age, with a particularly sharp rise after 60 years. This is primarily due to the cumulative effects of other risk factors and the natural aging process on arterial health [1].
2. Gender
While PAD was historically considered more prevalent in men, recent epidemiological data suggest that the global prevalence of PAD is generally higher in females than in males, especially in older age groups [1]. However, men often present with more severe symptoms and higher rates of amputation.
3. Genetics
Genetic predisposition also plays a role in the development of PAD. A family history of PAD or other atherosclerotic diseases increases an individual's risk, suggesting a genetic component in susceptibility to the condition [10].
IV. Geographic and Socio-Demographic Variations
The global burden of PAD is not uniformly distributed; significant variations exist across different geographic regions and socio-demographic groups, influenced by a complex interplay of genetic, environmental, and socioeconomic factors.
A. Regional Differences in Prevalence and Burden
The prevalence of PAD varies considerably by region. While the total number of people with PAD has increased globally, the distribution of this increase is not even. For instance, in 2019, 42.6% of the global PAD burden was concentrated in countries with low to middle Socio-demographic Index (SDI) [1]. This highlights a disproportionate burden in these regions, often linked to limited healthcare access, lower awareness, and a higher prevalence of unmanaged risk factors.
B. Impact of Socio-Demographic Index (SDI)
The Socio-demographic Index (SDI) is a composite measure of development status, encompassing income per capita, educational attainment, and total fertility rate. The relationship between SDI and PAD prevalence is complex. The prevalence of PAD was found to be highest in countries with high SDI and lowest in countries with low SDI [1]. However, DALY and mortality rates showed a U-shaped curve, indicating the highest burden in both high and low SDI quintiles [1]. This suggests that while high-income countries may have a higher prevalence due to factors like an aging population and better diagnostic capabilities, low-income countries face a significant burden in terms of severe outcomes (DALYs and mortality) due to inadequate prevention and treatment.
C. Gender-Specific Trends
Historically, PAD was often considered a male-predominant disease. However, recent data from the GBD 2019 study indicate that the global prevalence of peripheral artery disease was generally higher in females than in males [1]. Despite this, males and low-income countries showed similar DALY rates to females and higher-income countries, highlighting a disproportionate burden in these groups [1]. This suggests that while women may have a higher prevalence, men might experience more severe forms or complications of the disease, or there might be differences in diagnosis and reporting.
V. Public Health Implications and Management Strategies
The escalating global burden of PAD necessitates robust public health interventions and comprehensive management strategies to mitigate its impact on individuals and healthcare systems.
A. Healthcare Burden and Economic Impact
PAD imposes a significant burden on healthcare systems worldwide. The costs associated with diagnosis, treatment (including revascularization procedures and amputations), and long-term care for PAD patients are substantial. The economic impact extends to lost productivity due to disability and premature mortality. As the prevalence and severity of PAD are projected to rise, so too will the economic strain, particularly in low- and middle-income countries where resources are often limited [2].
B. Importance of Early Diagnosis and Intervention
Early diagnosis of PAD is critical for improving patient outcomes. Many individuals with PAD are asymptomatic or have atypical symptoms, leading to underdiagnosis and delayed intervention. Screening high-risk individuals, such as those with diabetes, hypertension, or a history of smoking, using non-invasive methods like the Ankle-Brachial Index (ABI), can facilitate early detection. Prompt intervention, including lifestyle modifications, pharmacotherapy, and revascularization when indicated, can prevent disease progression, reduce the risk of limb loss, and improve cardiovascular outcomes [7].
C. Role of Risk Factor Modification
Given that modifiable risk factors account for a substantial portion of the global PAD burden (around 70% in 2019) [1], public health initiatives focused on risk factor modification are paramount. Comprehensive programs addressing smoking cessation, blood pressure control, diabetes management, lipid-lowering, and promotion of healthy lifestyles (diet and exercise) can significantly reduce the incidence and progression of PAD. These efforts require a multi-faceted approach involving public awareness campaigns, policy changes, and accessible healthcare services.
VI. Conclusion
A. Summary of Key Findings
Peripheral Arterial Disease represents a growing global health challenge, with its prevalence and associated morbidity and mortality projected to increase significantly in the coming decades. The disease disproportionately affects older populations and exhibits complex geographic and socio-demographic variations. Modifiable risk factors, particularly smoking, diabetes, hypertension, and dyslipidemia, are major drivers of the PAD epidemic, accounting for a substantial portion of its global burden. While advances in diagnosis and treatment have been made, the sheer scale of the problem necessitates a renewed focus on prevention.
B. Call to Action for Prevention and Management
Addressing the global burden of PAD requires a concerted effort from healthcare providers, policymakers, and individuals. Prioritizing public health initiatives aimed at widespread risk factor modification, improving early detection strategies, and ensuring equitable access to effective treatments are essential. By implementing comprehensive prevention and management programs, we can strive to reduce the devastating impact of PAD, improve patient quality of life, and alleviate the growing strain on global healthcare resources.
VII. Disclaimer
**Disclaimer:** This blog post is intended for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article. INVAMED does not endorse any specific treatments or procedures mentioned herein. For personalized medical guidance, please consult with a healthcare professional.
References
[1] GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Global Health. October 2023. [https://www.healthdata.org/research-analysis/library/global-burden-peripheral-artery-disease-and-its-risk-factors-1990-2019](https://www.healthdata.org/research-analysis/library/global-burden-peripheral-artery-disease-and-its-risk-factors-1990-2019) [2] Deng, L., Du, C., Liu, L., Wang, Y., Gu, H., Armstrong, D. G., ... & Deng, W. (2025). Forecasting the Global Burden of Peripheral Artery Disease from 2021 to 2050: A Population-Based Study. Research, 8422768. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12209533/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12209533/) [3] Liu, W., et al. (2025). A systematic analysis of global burden of disease study 2021. Frontiers in Cardiovascular Medicine. [https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1603810/pdf](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1603810/pdf) [4] You, Y., Wang, Z., Yin, Z., Bao, Q., Lei, S., Yu, J., ... & Xie, X. (2023). Global disease burden and its attributable risk factors of peripheral arterial disease. Scientific Reports, 13(1), 20500. [https://www.nature.com/articles/s41598-023-47028-5](https://www.nature.com/articles/s41598-023-47028-5) [5] Norgren, L., et al. (2007). Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery, 33(Suppl 1), S1-S75. [6] Shu, J., & Santulli, G. (2018). Update on peripheral artery disease: Epidemiology, management, and novel therapeutic strategies. Journal of Atherosclerosis and Thrombosis, 25(9), 800-810. [7] Aboyans, V., et al. (2018). 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 39(9), 763-816. [8] Criqui, M. H., & Aboyans, V. (2015). Epidemiology of peripheral artery disease. Circulation Research, 116(9), 1509-1526. [9] Fowkes, F. G. R., et al. (2017). Ankle Brachial Index (ABI) and the risk of cardiovascular events and mortality: a systematic review and meta-analysis. European Heart Journal, 38(25), 1996-2003. [10] Murabito, J. M., et al. (2014). Genetic risk factors for peripheral artery disease. Circulation, 129(14), 1593-1600.